International HIT-MED Registry

Author: Julia Dobke, erstellt am: 2015/02/12, Last modification: 2019/09/17

International HIT-MED Registry International HIT-MED Registry: for children, adolescents, and adults with medulloblastoma, ependymoma, pineoblastoma, CNS-primitive neuroectodermal tumours
Disease Medulloblastoma, Ependimoma, Pineoblastoma, CNS-PNET
Type Registry
Problem / Objectives
  • To evaluate clinical data on the epidemiology of the above mentioned CNS-neoplasms, and the use and outcome of different treatment regimens, for patients who cannot be included in prospective trials.
  • To provide guidelines to establish, maintain and improve systems for quality assurance in the diagnostic assessments and treatment of brain tumours.
  • To collect biological specimens (tumour, CSF, peripheral blood) and perform comprehensive biological studies with the aim to improve our understanding of these diseases and their aetiology, to improve therapy stratification and to improve or develop new treatment options.
  • To collect clinical data for cooperative scientific projects (e.g. new follow-up studies, studies on quality of survival, neuropsychology etc.)
Inclusion Criteria
  • Children and adults with histologically proven: Medulloblastoma (MB); Ependymoma; CNS-primitive neuroectodermal tumours -CNS-PNET- ( including CNS neuroblastoma, CNS ganglioneuroblastoma, Medulloepithelioma, Ependymoblastoma); Pineoblastoma; Pineal parenchymal tumour of intermediate differentiation; Papillary tumour of the pineal region
  • All ages (except for ependymoma WHO I°, pineal parenchymal tumour of intermediate differentiation and papillary tumour of the pineal region, who will be registered only if primary diagnosis was before the 18th birthday)
  • Any localisation of the primary tumour
  • All clinical stages
Exclusion Criteria
  • Registration in another clinical trial for the same diagnosis (relapse is defined as a second diagnosis).
  • Lack of valid ethical committee approval.
Status start: 01/01/2015
Principal Investigator Prof. Dr. med. Stefan Rutkowski
E-Mail hitchem@uke.de
Contact

International Coordinator

Prof. Dr. med. Stefan Rutkowski Universitätsklinikum Hamburg-Eppendorf Klinik u. Poliklinik f. Päd. Onkologie u. Hämatologie, Haus N21 Martinistr. 52 20246 Hamburg Telefon +49 (40) 7410 58200 Fax +49 (40) 7410 58300 s.rutkowski@uke.de

Clinical Trial Manger

Regine Riechers Universitätsklinikum Hamburg-Eppendorf Klinik für Pädiatrische Hämatologie und Onkologie Martinistr. 52 20246 Hamburg Telefon +49 (0)40 74 10-567 76 Fax +49 (0)40 74 10-5 83 00 r.riechers@uke.de

Data Manager

Susanne Becker Uni­ver­si­täts­kli­ni­kum Ham­burg-Ep­pen­dorf Kli­nik u. Po­li­kli­nik f. Päd. On­ko­lo­gie u. Hä­ma­to­lo­gie, Haus N21, HIT-MED Studienzentrale Martinistr. 52 20246 Ham­burg Telefon +49 (40) 7410 58200 Fax +49 (40) 7410 58300 hitchem@uke.de

Antje Stiegmann Universitätsklinikum Hamburg-Eppendorf Kli­nik u. Po­li­kli­nik f. Päd. On­ko­lo­gie u. Hä­ma­to­lo­gie, Haus N21, HIT-MED Stu­di­en­zen­tra­le Martinistr. 52 20246 Hamburg Telefon +49 (40) 7410 58200 Fax +49 (40) 7410 58300 hitchem@uke.de

Participants Deutschland, Östereich, Schweiz
Link(s) Publications
Sponsoring Deutsche Kinderkrebsstiftung, Damp-Stiftung, Fördergemeinschaft Kinderkrebszentrum Hamburg